- Home
- NAUT vs RCKT Comparison
NAUT vs RCKT Comparison
Compare NAUT & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAUT | RCKT |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.5M | 401.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | NAUT | RCKT |
|---|---|---|
| Price | $2.39 | $2.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 14 |
| Target Price | $4.00 | ★ $29.73 |
| AVG Volume (30 Days) | 424.8K | ★ 2.2M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $992.86 | $64.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.62 | $2.40 |
| 52 Week High | $4.31 | $5.45 |
Technical Indicators
Market Signals| Indicator | NAUT | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 40.93 | 30.63 |
| Support Level | $2.22 | N/A |
| Resistance Level | $2.54 | $3.42 |
| Average True Range (ATR) | 0.19 | 0.17 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 15.00 | 7.04 |
Price Performance
Historical ComparisonAbout NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.